Immune checkpoint inhibitors are becoming standard treatments in several cancer types,
profoundly changing the prognosis of a fraction of patients. Currently, many efforts are being …

Myeloid-derived suppressor cell (MDSC) is a heterogeneous population of immature
myeloid cells, has a pivotal role in negatively regulating immune response, promoting tumor …

Background Cancer immunotherapy is associated with several immune-related adverse
events, but the relationship between immunotherapy and venous thromboembolism has not …

Purpose: Treatment options are limited in patients with metastatic neuroendocrine
neoplasms (NEN). We present the results for a phase II trial of combination nivolumab and …

Objectives: To examine patient and disease characteristics, toxicity, and clinical outcomes
for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune …

The spread of primary tumor cells to distant organs, termed metastasis, is the principal cause
of cancer mortality and is a critical therapeutic target in oncology. Thus, a better …

Myeloid‐derived suppressor cells (MDSCs) are an immature group of myeloid‐derived cells
generated from myeloid cell precursors in the bone marrow. MDSCs appear almost …

Background Inhibition of the programmed cell death protein 1 (PD‐1) pathway has
demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates …

The management of advanced (locally advanced or metastatic) urothelial carcinoma has
been revolutionized since pembrolizumab was introduced in 2017. Several prognostic …

Background Myeloid-derived suppressor cells (MDSCs) were linked to pathologic stage in
bladder urothelial carcinoma (UC). Neutrophil lymphocyte ratio (NLR) is an inflammatory …